4:40 PM ET
10-Q
Financial Results
Greenwich LifeSciences Q3 2026 Results: Net Loss of $5.81M, Loss Widens
Greenwich LifeSciences reported a net loss of $15.4 million for the nine months ended September 30, 2026, driven primarily by $14.2 million in research and development expenses for its breast cancer immunotherapy. The company raised $9.3 million through an ATM program during the period but issued a going concern warning due to its accumulated deficit of $102.6 million and limited cash reserves of $5.9 million.
- Key figure
- Net loss $5.81M